Retatrutide - Triple G 12 mg vial

Retatrutide characteristics

Retatrutide (LY3437943) is a synthetic peptide with a modified amino acid sequence designed to simultaneously activate GLP-1, GIP and glucagon receptors. Its chemical structure is based on a peptide skeleton inspired by natural incretin hormones, with the structural modifications used increasing the metabolic stability and half-life of the molecule. Structure-function studies indicate that the specific spatial conformation of retatrutide enables a multi-receptor interaction, which distinguishes it from classical incretin agonists with a simpler structure. Compared to common peptides such as Tirzepatyd or Semaglutide, Retatrutide shows a broader spectrum of action, stimulating GLP-1, GIP receptors and additionally glucagon. Triple g is intended for laboratory use as a reference standard and analytical material in qualitative studies, including HPLC.

See also Triple G reagent in 8 mg in the device

Mechanism of action of retatrutide (scientific data)

According to preclinical and clinical studies, retatrutide acts as a triple agonist of GLP-1, GIP and glucagon receptors, affecting appetite regulation, glucose metabolism and energy expenditure. Activation of the GLP-1 and GIP pathways promotes improved glycaemic control and reduced energy intake, while glucagon receptor involvement is associated with increased energy expenditure and enhanced lipolysis. According to the authors of the publication, simultaneous modulation of these receptors leads to a synergistic metabolic effect.

Retatrutide - clinical trial data

According to the results of a randomised phase 2 clinical trial, retatrutide showed a significant effect on weight reduction in adults with obesity. The authors of the pivotal study report that after 48 weeks, a mean weight reduction of approximately 22.8% was observed at the 8 mg dose and up to 24.2% at the 12 mg dose, compared to baseline values.

In addition, clinical trials reported improved glycaemic control (including a reduction in HbA1c) and beneficial changes in metabolic parameters. Subgroup analyses in people with type 2 diabetes indicated that weight loss was largely associated with a reduction in body fat, with relative maintenance of fat-free mass. According to the authors of the publication, these results suggest a potentially broader metabolic effect compared with classical incretin agonists.

Scientific sources:

1. PubMed ID (PMID): 37366315 Jastreboff A.M. et al.
   Triple-Hormone Receptor Agonist Retatrutide for Obesity.
   New England Journal of Medicine, 2023.
2. PubMed ID (PMID): 38323122 Naeem M. et al.
   Unleashing the power of retatrutide: A possible triumph over obesity and overweight.
3. PubMed ID (PMID): 37385280 - retatrutide clinical trials
   Retatrutide, a GIP, GLP-1 and glucagon receptor agonist...
4. PubMed ID (PMID): 40609566
   Effects of retatrutide on body composition in people with type 2 diabetes

The product is intended for scientific research and laboratory analysis. All articles and information on this website are for informational and educational purposes only.